Form 8-K - Current report:
SEC Accession No. 0001370053-25-000002
Filing Date
2025-02-03
Accepted
2025-02-03 08:55:32
Documents
19
Period of Report
2025-01-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K anab-20250131.htm   iXBRL 8-K 27888
2 EX-99.1 anab-pressrelease2025x01.htm EX-99.1 13945
7 anab-pressrelease2025x01001.jpg GRAPHIC 250230
8 anab-pressrelease2025x01002.jpg GRAPHIC 291109
9 anab-pressrelease2025x01003.jpg GRAPHIC 288998
10 anab-pressrelease2025x01004.jpg GRAPHIC 175524
  Complete submission text file 0001370053-25-000002.txt   1601196

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anab-20250131.xsd EX-101.SCH 2058
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anab-20250131_def.xml EX-101.DEF 8934
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anab-20250131_lab.xml EX-101.LAB 30000
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anab-20250131_pre.xml EX-101.PRE 20656
21 EXTRACTED XBRL INSTANCE DOCUMENT anab-20250131_htm.xml XML 2817
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 25580776
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)